2015-01-06 18:55:04 UTC

Vasopressor Terlipressin Helped Patients with Cirrhosis, Shock

Jan. 8, 2015

Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients. Read more in

Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients.

Terlipressin also seemed to provide advantages over noradrenaline by contributing to greater hemodynamic stability, improved urine output, reduced variceal bleeding, a lower risk of spontaneous bacterial peritonitis, and reduced mortality in the first 48 hours, but not at 28 days.

Read more in GI & Hepatology News.

More on Cirrhosis

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Blog: Diagnosis, Pathogenesis and Treatment of Hepatorenal Syndrome in Patients With Cirrhosis

Jan. 30, 2018

New concepts and developments for diagnosis and assessment of renal function in patients with cirrhosis. Read more on the AGA Journals Blog.

Image Challenge: Cullen's Sign

Jan. 22, 2018

What caused a 56-year-old man with a previous history of cirrhosis to present with a large volume of ascites and periumbilical ecchymosis?